Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00075179 · ClinicalTrials.gov registry record · Phase 4

Natrecor in Pulmonary Hypertension

A Phase 4 study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
Phase 4
Development phase
15
Enrollment target

NCT00075179: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.

NCT00075179 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00075179, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.

Interventions

  • PROCEDURE Right Heart Catheterization
  • DRUG Nesiritide (Natrecor)

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2003-12-31
Est. Completion 2006-03-28
Phase Phase 4
M.D. Anderson Cancer Center

2,692 total trials

Why NCT00075179 stopped before completion

NCT00075179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Right Heart Catheterization is the first listed.

NCT00075179 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00075179 about?

NCT00075179 is a clinical study titled "Natrecor in Pulmonary Hypertension". The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a ...

What is the current status of trial NCT00075179?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2003-12-31. Estimated completion is 2006-03-28.

What interventions are being tested in trial NCT00075179?

The interventions under investigation include: Right Heart Catheterization (PROCEDURE), Nesiritide (Natrecor) (DRUG).

Who is sponsoring clinical trial NCT00075179?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00075179's enrollment target sits among peer trials

15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00075179, the US trial registry maintained by the National Library of Medicine. NCT00075179 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.